Aromics launches a crowdfunding campaign to accelerate the development of a novel drug for the treatment of asbestos-related cancer Blog Post

The biotech company Aromics, located at the Barcelona Science Park (PCB), has launched an equity crowdfunding campaign through the European platform CapitalCell, with the goal of raising a capital round up to 300,000€ for completing the preclinical package of its compound NAX035, a novel first-in-class drug for the treatment of malignant mesothelioma, a rare, aggressive and highly treatment-resistant asbestos-associated malignancy.

 

Aromics and Iproteos present their projects at 16th Healthcare Investment Forum Blog Post

Aromics and Iproteos, based at the Barcelona Science Park, have been selected to present their innovation projects at 16th Healthcare Investment Forum, which took place on 9th March at the meeting room of the Barcelona Medical Association (COMB). The workshop, organised by Biocat, Esade BAN, Barcelona Activa and COMB, aims to create a meeting point for companies in the healthcare sector and investors who might be interested in funding their idea or product. Since 2009, this initiative has helped lunch over 100 companies following a selection process that evaluated about 400 projects.